CL2020000973A1 - Composiciones y procedimientos para el tratamiento de linfoma difuso de celulas b grandes. - Google Patents

Composiciones y procedimientos para el tratamiento de linfoma difuso de celulas b grandes.

Info

Publication number
CL2020000973A1
CL2020000973A1 CL2020000973A CL2020000973A CL2020000973A1 CL 2020000973 A1 CL2020000973 A1 CL 2020000973A1 CL 2020000973 A CL2020000973 A CL 2020000973A CL 2020000973 A CL2020000973 A CL 2020000973A CL 2020000973 A1 CL2020000973 A1 CL 2020000973A1
Authority
CL
Chile
Prior art keywords
procedures
compositions
treatment
cell lymphoma
diffuse large
Prior art date
Application number
CL2020000973A
Other languages
English (en)
Inventor
Zachary ZIMMERMAN
Xiaohong Alicia Zhang
Peter Christopher Holland
Janet Franklin
Gregory Friberg
Original Assignee
Merck Sharp & Dohme
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Amgen Inc filed Critical Merck Sharp & Dohme
Publication of CL2020000973A1 publication Critical patent/CL2020000973A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CL2020000973A 2017-10-13 2020-04-09 Composiciones y procedimientos para el tratamiento de linfoma difuso de celulas b grandes. CL2020000973A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762571870P 2017-10-13 2017-10-13

Publications (1)

Publication Number Publication Date
CL2020000973A1 true CL2020000973A1 (es) 2020-12-28

Family

ID=64110107

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000973A CL2020000973A1 (es) 2017-10-13 2020-04-09 Composiciones y procedimientos para el tratamiento de linfoma difuso de celulas b grandes.

Country Status (15)

Country Link
US (1) US20200262919A1 (es)
EP (1) EP3694520A1 (es)
JP (2) JP2020536923A (es)
KR (1) KR20200068655A (es)
CN (1) CN111212646A (es)
AU (1) AU2018347457A1 (es)
BR (1) BR112020007203A2 (es)
CA (1) CA3075291A1 (es)
CL (1) CL2020000973A1 (es)
EA (1) EA202090565A1 (es)
IL (1) IL273805A (es)
MX (1) MX2020003395A (es)
SG (1) SG11202002374RA (es)
TW (1) TW201922283A (es)
WO (1) WO2019075366A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008266951B2 (en) 2007-06-18 2013-12-12 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor PD-1
TW202200615A (zh) * 2020-03-12 2022-01-01 美商安進公司 用於治療和預防患者的crs之方法
WO2024097218A1 (en) * 2022-11-01 2024-05-10 TeneoTwo, Inc. Methods of treating non-hodgkin lymphoma

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3856559T2 (de) 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
NZ507381A (en) 1998-04-21 2003-12-19 Micromet Ag CD19xCD3 specific polypeptides and uses thereof
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
BRPI0809594A2 (pt) 2007-04-03 2019-08-27 Micromet Ag polipeptídeo, seqüência de ácido nucléico, vetor, hospedeiro, processo para a produção de um polipeptídeo, composição farmacêutica, uso de um polipeptídeo, método para prevenção, tratamento ou melhora de uma doença, em um indivíduo com necessidade do mesmo, kit, método para a identificação de um polipeptídeo(s)
AU2008266951B2 (en) 2007-06-18 2013-12-12 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor PD-1
WO2016019969A1 (en) * 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität München Subcutaneously administered bispecific antibodies for use in the treatment of cancer
BR112017025562A2 (pt) 2015-05-29 2018-08-07 Merck Sharp & Dohme Corp. métodos para tratar câncer em um indivíduo e para tratar um indivíduo humano diagnosticado com câncer
KR20180023968A (ko) * 2015-07-02 2018-03-07 셀진 코포레이션 혈액암 및 충실성 종양의 치료를 위한 병용 요법

Also Published As

Publication number Publication date
US20200262919A1 (en) 2020-08-20
JP2024001071A (ja) 2024-01-09
IL273805A (en) 2020-05-31
MX2020003395A (es) 2020-08-03
BR112020007203A2 (pt) 2020-10-20
CN111212646A (zh) 2020-05-29
EP3694520A1 (en) 2020-08-19
EA202090565A1 (ru) 2020-10-13
CA3075291A1 (en) 2019-04-18
AU2018347457A1 (en) 2020-04-09
KR20200068655A (ko) 2020-06-15
JP2020536923A (ja) 2020-12-17
SG11202002374RA (en) 2020-04-29
TW201922283A (zh) 2019-06-16
WO2019075366A1 (en) 2019-04-18

Similar Documents

Publication Publication Date Title
IL264049A (en) Compounds, preparations and methods for treating the disease
EP3494565A4 (en) COGNITIVE PLATFORM INCLUDING COMPUTERIZED EVOCATORY ELEMENTS
IL264156A (en) Compounds, preparations and methods for treating the disease
SG11202005062SA (en) Electrochemical methods, devices and compositions
CL2018000565A1 (es) Compuestos derivados de piridinona dicarboxamida, inhibidores de bromodominio; composicion farmaceutica; combinacion farmaceutica; utiles en el tratamiento de enfermedades autoinmunitarias, inflamatorias, virales y cancer, entre otras.
EP3538189A4 (en) COMPOSITIONS, DEVICES AND METHODS FOR TREATING OPIOID RECEPTOR-MEDIATED STATES
GB2588261B (en) Apparatus, use of the apparatus and arrangement
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
DE112015002461T8 (de) Kautschukzusammensetzung und diese verwendendes Förderband
CL2020000973A1 (es) Composiciones y procedimientos para el tratamiento de linfoma difuso de celulas b grandes.
BR112017005126A2 (pt) compostos citotóxicos e antimitóticos e métodos de uso dos mesmos.
CL2018001502A1 (es) Procedimiento para el tratamiento de efluente acuoso.
ZA201903928B (en) Compositions comprising methylphenidate-prodrugs, processes of making and using the same
IL271728A (en) Materials, uses and treatment methods
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
EP3449924A4 (en) COMPOSITION, ACTIVE SITE OF CROCINES, AND USES THEREOF
DK3302478T3 (da) Pac-1 kombinations behandling
IL272738A (en) treatment regimens
HK1251449A1 (zh) 用於治療2型糖尿病的交聯聚二烯丙基胺共聚物
ES2759940T8 (es) Compuestos de 1,3,4-tiadiazol y su uso para tratar el cáncer
SG11201700120XA (en) Coix seed oil comprising 13 glycerides, formulation and application thereof
SG11201700124SA (en) Coix seed oil comprising 16 glycerides, formulation and application thereof
IT201700039351A1 (it) Miscela antimeristematica e antigermogliante
MA41125A (fr) Dérivés de 6.7-cyclomorphinane et leur utilisation
ZA201904328B (en) Composition, application thereof and treatment method